Compare MHH & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHH | ACET |
|---|---|---|
| Founded | 1986 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.7M | 69.6M |
| IPO Year | 2008 | 2017 |
| Metric | MHH | ACET |
|---|---|---|
| Price | $6.26 | $7.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $65.33 |
| AVG Volume (30 Days) | 15.5K | ★ 130.1K |
| Earning Date | 05-22-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.90 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $198,943,000.00 | N/A |
| Revenue This Year | $2.93 | N/A |
| Revenue Next Year | $8.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.51 | $0.45 |
| 52 Week High | $10.91 | $9.05 |
| Indicator | MHH | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 45.43 | 52.71 |
| Support Level | $5.51 | $6.54 |
| Resistance Level | $7.75 | $8.46 |
| Average True Range (ATR) | 0.37 | 0.48 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 65.09 | 49.66 |
Mastech Digital Inc is a provider of Digital Transformation IT Services. The Company offers data & analytics solutions & IT staffing services for both digital & mainstream technologies. The Group has two segments. Its Data & Analytics Services segment delivers specialized data management, data engineering, customer experience consulting, data analytics & cloud services to customers globally. IT Staffing Services segment combines technical expertise with business process experience to deliver a broad range of services in digital & mainstream technologies. The company derives a majority of its revenue from IT staffing services. Geographically, the majority of revenue is generated from the United States.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.